ArticleP & T : a peer-reviewed journal for formulary management2014
Epilepsy management: newer agents, unmet needs, and future treatment strategies.
Article in P & T : a peer-reviewed journal for formulary management, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 35 citations in OpenAlex.
- Trial
- Antiepileptic and antiepileptogenic effects ofIBRO neuroscience reports · 2026Article
- Advancing the Paradigm of Temporal Lobe Epilepsy as a Network Disease: The Promise of Biomarkers and Targeted Disease Modification.International journal of molecular sciences · 2026Review
- Iron single-atom nanozyme-mediated laser interstitial thermal therapy and anti-inflammatory effect for epilepsy.Materials today. Bio · 2026Article
- Health Care Costs After Genome-Wide Sequencing for Children With Rare Diseases in England and Canada.JAMA network open · 2024Article
- Understanding Health Care Provider Burnout When Caring for Patients With Refractory Epilepsy in the United States.Neurology. Clinical practice · 2024Article
- Cost-Utility Analysis of Add-on Cannabidiol vs Usual Care Alone for the Treatment of Seizures in Patients With Treatment-Resistant Lennox-Gastaut Syndrome or Dravet Syndrome in the Netherlands.Journal of health economics and outcomes research · 2024Article
- Cenobamate for treatment-resistant focal seizures: current evidence and place in therapy.Journal of central nervous system disease · 2022Review
- Brivaracetam Retention Rate and Seizure Outcomes in Patients with Drug-Resistant Focal Epilepsy Included in the Medical Need Program in Belgium: A Real-World, Multicenter, Chart Review.Drugs - real world outcomes · 2021Article
- Rapamycin, but not minocycline, significantly alters ultrasonic vocalization behavior in C57BL/6J pups in a flurothyl seizure model.Behavioural brain research · 2021Article
- Pharmacological and Therapeutic Approaches in the Treatment of Epilepsy.Biomedicines · 2021Review
- Montelukast: The New Therapeutic Option for the Treatment of Epilepsy.Journal of experimental pharmacology · 2021Review
- Observational
- Wnt/β-catenin signaling as a potential target for novel epilepsy therapies.Epilepsy research · 2018Review
- Review
- Real life pharmaceutical treatment patterns for adult patients with focal epilepsy in Germany: a longitudinal and cross-sectional analysis of recently approved anti-epileptic drugs.German medical science : GMS e-journal · 2017Article
- Pharmacological Analysis of the Anti-epileptic Mechanisms of Fenfluramine inFrontiers in pharmacology · 2017Article
- Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Drug therapy aids most epilepsy patients, but unmet challenges include drug-resistant epilepsy, adverse reactions, drug interactions, the need to better identify epileptic syndromes, and a lack of agents to prevent epilepsy and its comorbidities.
Identifiers
25395820PMC4218673W2266846713What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.